I-Mab’s pipeline pivot had a sting in the tail. Weeks after shifting its focus, the biotech said Wednesday that it has reduced its workforce by around 27% in conjunction with the pipeline ...

ROCKVILLE, Md., March 07, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (the “Company”), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents ...

I-Mab, the Rockville-based global biotech company focused on cancer treatment, Wednesday announced it has entered into a clinical trial collaboration and supply agreement with Bristol Myers Squibb ...